InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,722.80
(
0.23%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.77
(
0.46%
)
Bitcoin
63,038.63
(
2.59%
)
Post# of 111
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

e-ore

Send PM Follow Ignore
Followers 281
Posts 25967
Boards Moderated 6
Alias Born 01/27/2009

e-ore

Member Level

Re: e-ore post# 31

Wednesday, 01/27/2016 10:46:35 PM

Wednesday, January 27, 2016 10:46:35 PM

Post# of 111
AGX-51 patented by AGGX. Dr Benezra is AGGX's lead researcher, a director and a shareholder. His lab is at Memorial Sloan Kettering. MSK a shareholder too. AGGX website still under construction.

"Dr. Benezra’s team identified an agent called AGX-51 that reduces the levels of Id1 and Id3 proteins leading to a decrease in lung metastases. When combined with the commonly used chemotherapy drug Taxol, AGX-51 further reduced lung metastases in a model of aggressive breast cancer."

From here:
https://labnodes.vanderbilt.edu/member/publication/id/12249/pmid/26084673

"We then performed in vivo experiments and found that the Id1 inhibitor significantly prolonged the survival of t(8;21)(+) leukemic mice"

My posts are my opinion. Do not be influenced by anything you read on any message board website unless you can confirm it.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up